Agnesska C. Benjamin
Research Subjects
Agnesska C. Benjamin has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Gillian P. Bates
Department of Neurodegenerative Disease, Huntington’s Disease Centre, Queen Square Institute of Neurology, University College London, London WC1N 3BG, UK
6 shared publications - Sophie E. Acton
University College London
4 shared publications - Eva Crosas-Molist
Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet, Barcelona, Spain
3 shared publications - Valerio Imperatore
Stromal Immunology Group, MRC Laboratory for Molecular Cell Biology, University College London, Gower Street, London WC1E 6BT, UK
3 shared publications - Yukti Hari-Gupta
Stromal Immunology Laboratory, MRC Laboratory for Molecular Cell Biology, University College London, London, United Kingdom
3 shared publications Alexander Carver
Stromal Immunology Group, MRC Laboratory for Molecular Cell Biology, University College London, Gower Street, London WC1E 6BT, UK
2 shared publications
Latest Publications
- Open Access
The Extracellular Matrix Regulates Tissue Mechanics to Enable Cyclic Lymph Node Remodelling for Sustained Immunity
Tissue shape and function are defined by the mechanical interactions of cellular and extracellular components. Lymph nodes cyclically remodel in response to immune challenges whilst preserving essential tissue architecture, comprised of a stromal fibroblastic reticular cell (FRC) network and extracellular matrix (ECM) it ensheaths. We experimentally quantified the contribution of ECM to the viscoelastic properties of the FRC network to parameterise an in silico model exploring factors affecting the FRC network's adaptation to lymph node expansion. The balance between tissue pressure, FRC contractility, and ECM stiffness permit robust tissue remodelling, while maintaining physiological geometries. Local perturbation of ECM stiffness or FRC contractility disrupts force distribution and impacts FRC proliferation and tissue expansion. Spatially dispersed perturbations exert higher impact on tissue remodelling than equivalent localised perturbations, with effects propagating across the network. The lymph node provides a system for studying the integration of cellular and extracellular mechanics during dramatic tissue remodelling.
Open AccessThe Extracellular Matrix Regulates Tissue Mechanics to Enable Cyclic Lymph Node Remodelling for Sustained Immunity
Tissue shape and function are defined by the mechanical interactions of cellular and extracellular components. Lymph nodes cyclically remodel in response to immune challenges whilst preserving essential tissue architecture, comprised of a stromal fibroblastic reticular cell (FRC) network and extracellular matrix (ECM) it ensheaths. We experimentally quantified the contribution of ECM to the viscoelastic properties of the FRC network to parameterise an in silico model exploring factors affecting the FRC network's adaptation to lymph node expansion. The balance between tissue pressure, FRC contractility, and ECM stiffness permit robust tissue remodelling, while maintaining physiological geometries. Local perturbation of ECM stiffness or FRC contractility disrupts force distribution and impacts FRC proliferation and tissue expansion. Spatially dispersed perturbations exert higher impact on tissue remodelling than equivalent localised perturbations, with effects propagating across the network. The lymph node provides a system for studying the integration of cellular and extracellular mechanics during dramatic tissue remodelling.
- Open Access
Podoplanin drives dedifferentiation and amoeboid invasion of melanoma
Melanoma is an aggressive skin cancer developing from melanocytes, frequently resulting in metastatic disease. Melanoma cells utilise amoeboid migration as mode of local invasion. Amoeboid invasion is characterized by rounded cell morphology and high actomyosin contractility driven by the RhoA signalling pathway. Migrastatic drugs targeting actin polymerization and contractility to inhibit invasion and metastasis are therefore a promising treatment option. To predict amoeboid invasion and metastatic potential, there is a need for biomarkers functionally linked to contractility pathways. The glycoprotein podoplanin drives actomyosin contractility in lymphoid fibroblasts, and is overexpressed in several cancer types. Here, we show that podoplanin enhances amoeboid invasion in melanoma. Expression of podoplanin in murine melanoma models drives rounded cell morphology, increasing motility and invasion in vivo . Podoplanin expression is upregulated in a subset of dedifferentiated human melanoma, and in vitro is sufficient to suppress melanogenesis and upregulate melanoma-associated markers Mitf and Pou3f2 . Together, our data indicates that podoplanin is both a potential biomarker for dedifferentiated invasive melanoma and a promising migrastatic therapeutic target.
Open AccessPodoplanin drives dedifferentiation and amoeboid invasion of melanoma
Melanoma is an aggressive skin cancer developing from melanocytes, frequently resulting in metastatic disease. Melanoma cells utilise amoeboid migration as mode of local invasion. Amoeboid invasion is characterized by rounded cell morphology and high actomyosin contractility driven by the RhoA signalling pathway. Migrastatic drugs targeting actin polymerization and contractility to inhibit invasion and metastasis are therefore a promising treatment option. To predict amoeboid invasion and metastatic potential, there is a need for biomarkers functionally linked to contractility pathways. The glycoprotein podoplanin drives actomyosin contractility in lymphoid fibroblasts, and is overexpressed in several cancer types. Here, we show that podoplanin enhances amoeboid invasion in melanoma. Expression of podoplanin in murine melanoma models drives rounded cell morphology, increasing motility and invasion in vivo . Podoplanin expression is upregulated in a subset of dedifferentiated human melanoma, and in vitro is sufficient to suppress melanogenesis and upregulate melanoma-associated markers Mitf and Pou3f2 . Together, our data indicates that podoplanin is both a potential biomarker for dedifferentiated invasive melanoma and a promising migrastatic therapeutic target.
- Open Access
- 1 January 2020
- Published by Elsevier in SSRN Electronic Journal
Podoplanin Drives Dedifferentiation and Amoeboid Invasion of Melanoma
Melanoma is an aggressive skin cancer developing from melanocytes, frequently resulting in metastatic disease. Melanoma cells utilise amoeboid migration as mode of local invasion. Amoeboid invasion is characterized by rounded cell morphology and high actomyosin contractility driven by the RhoA signalling pathway. Migrastatic drugs targeting actin polymerization and contractility to inhibit invasion and metastasis are therefore a promising treatment option. To predict amoeboid invasion and metastatic potential, there is a need for biomarkers functionally linked to contractility pathways. The glycoprotein podoplanin drives actomyosin contractility in lymphoid fibroblasts, and is overexpressed in several cancer types. Here, we show that podoplanin enhances amoeboid invasion in melanoma. Expression of podoplanin in murine melanoma models drives rounded cell morphology, increasing motility and invasion in vivo. Podoplanin expression is upregulated in a subset of dedifferentiated human melanoma, and in vitro is sufficient to suppress melanogenesis and upregulate melanoma-associated markers Mitf and Pou3f2 . Together, our data indicates that podoplanin is both a potential biomarker for dedifferentiated invasive melanoma and a promising migrastatic therapeutic target.
- 1 January 2020
- Published by Elsevier in SSRN Electronic Journal
Open AccessPodoplanin Drives Dedifferentiation and Amoeboid Invasion of Melanoma
Melanoma is an aggressive skin cancer developing from melanocytes, frequently resulting in metastatic disease. Melanoma cells utilise amoeboid migration as mode of local invasion. Amoeboid invasion is characterized by rounded cell morphology and high actomyosin contractility driven by the RhoA signalling pathway. Migrastatic drugs targeting actin polymerization and contractility to inhibit invasion and metastasis are therefore a promising treatment option. To predict amoeboid invasion and metastatic potential, there is a need for biomarkers functionally linked to contractility pathways. The glycoprotein podoplanin drives actomyosin contractility in lymphoid fibroblasts, and is overexpressed in several cancer types. Here, we show that podoplanin enhances amoeboid invasion in melanoma. Expression of podoplanin in murine melanoma models drives rounded cell morphology, increasing motility and invasion in vivo. Podoplanin expression is upregulated in a subset of dedifferentiated human melanoma, and in vitro is sufficient to suppress melanogenesis and upregulate melanoma-associated markers Mitf and Pou3f2 . Together, our data indicates that podoplanin is both a potential biomarker for dedifferentiated invasive melanoma and a promising migrastatic therapeutic target.
- Open Access
- 27 September 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1-13
Regulatory mechanisms of incomplete huntingtin mRNA splicing
Huntington’s disease is caused by a CAG repeat expansion in exon 1 of theHTTgene. We have previously shown that exon 1HTTdoes not always splice to exon 2 producing a small transcript (HTTexon1) that encodes the highly pathogenic exon 1 HTT protein. The mechanisms by which this incomplete splicing occurs are unknown. Here, we have generated a minigene system that recapitulates the CAG repeat-length dependence ofHTTexon1production, and has allowed us to define the regions of intron 1 necessary for incomplete splicing. We show that manipulation of the expression levels of the splicing factor SRSF6, predicted to bind CAG repeats, modulates this aberrant splicing event and also demonstrate that RNA polymerase II transcription speed regulates the levels ofHTTexon1production. Understanding the mechanisms by which this pathogenic exon 1 HTT is generated may provide the basis for the development of strategies to prevent its production.
- 27 September 2018
- Published by Springer Nature in Nature Communications
- Vol. 9 (1) , 1-13
Open AccessRegulatory mechanisms of incomplete huntingtin mRNA splicing
Huntington’s disease is caused by a CAG repeat expansion in exon 1 of theHTTgene. We have previously shown that exon 1HTTdoes not always splice to exon 2 producing a small transcript (HTTexon1) that encodes the highly pathogenic exon 1 HTT protein. The mechanisms by which this incomplete splicing occurs are unknown. Here, we have generated a minigene system that recapitulates the CAG repeat-length dependence ofHTTexon1production, and has allowed us to define the regions of intron 1 necessary for incomplete splicing. We show that manipulation of the expression levels of the splicing factor SRSF6, predicted to bind CAG repeats, modulates this aberrant splicing event and also demonstrate that RNA polymerase II transcription speed regulates the levels ofHTTexon1production. Understanding the mechanisms by which this pathogenic exon 1 HTT is generated may provide the basis for the development of strategies to prevent its production.
- Open Access
- 30 July 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 1-14
In vivo neutralization of the protagonist role of macrophages during the chronic inflammatory stage of Huntington’s disease
Neurodegenerative diseases, characterised by the progressive and selective neuronal death in the central nervous system, are frequently accompanied by an activated immune system. In Huntington’s disease (HD), clinical and animal studies show evidence of immune activity, along with hyper-reactive monocyte/macrophage responses, while application of immunosuppressive regimens have imparted beneficial effects to HD mice. These findings suggest a contributory role of the immune system in HD pathology, with immune-based interventions offering a potential therapeutic strategy. Herein, we show that peripheral and CNS immune system activity increased with disease progression in HD mouse models and defined the phenotype of the immune response. Additionally, the depletion of monocytes and macrophagesin vivo, via clodronate liposome treatment, revealed a major contributory role of these innate immune cells to the chronic inflammatory milieu observed during the course of the disease. This suggests that peripheral immunomodulatory strategies targeting monocytes and macrophages could be relevant for HD.
- 30 July 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 1-14
Open AccessIn vivo neutralization of the protagonist role of macrophages during the chronic inflammatory stage of Huntington’s disease
Neurodegenerative diseases, characterised by the progressive and selective neuronal death in the central nervous system, are frequently accompanied by an activated immune system. In Huntington’s disease (HD), clinical and animal studies show evidence of immune activity, along with hyper-reactive monocyte/macrophage responses, while application of immunosuppressive regimens have imparted beneficial effects to HD mice. These findings suggest a contributory role of the immune system in HD pathology, with immune-based interventions offering a potential therapeutic strategy. Herein, we show that peripheral and CNS immune system activity increased with disease progression in HD mouse models and defined the phenotype of the immune response. Additionally, the depletion of monocytes and macrophagesin vivo, via clodronate liposome treatment, revealed a major contributory role of these innate immune cells to the chronic inflammatory milieu observed during the course of the disease. This suggests that peripheral immunomodulatory strategies targeting monocytes and macrophages could be relevant for HD.
- Open Access
- 19 September 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 1-13
Disruption to schizophrenia-associated gene Fez1 in the hippocampus of HDAC11 knockout mice
Histone Deacetylase 11 (HDAC11) is highly expressed in the central nervous system where it has been reported to have roles in neural differentiation. In contrast with previous studies showing nuclear and cytoplasmic localisation, we observed synaptic enrichment of HDAC11. Knockout mouse models for HDACs 1–9 have been important for guiding the development of isoform specific HDAC inhibitors as effective therapeutics. Given the close relationship between HDAC11 and neural cells in vitro, we examined neural tissue in a previously uncharacterised Hdac11 knockout mouse (Hdac11KO/KO). Loss of HDAC11 had no obvious impact on brain morphology and neural stem/precursor cells isolated from Hdac11KO/KO mice had comparable proliferation and differentiation characteristics. However, in differentiating neural cells we observed decreased expression of schizophrenia-associated gene Fez1 (fasciculation and elongation protein zeta 1), a gene previously reported to be regulated by HDAC11 activity. FEZ1 has been associated with the dendritic growth of neurons and risk of schizophrenia via its interaction with DISC1 (disrupted in schizophrenia 1). Examination of cortical, cerebellar and hippocampal tissue reveal decreased Fez1 expression specifically in the hippocampus of adult mice. The results of this study demonstrate that loss of HDAC11 has age dependent and brain-region specific consequences.
- 19 September 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 1-13
Open AccessDisruption to schizophrenia-associated gene Fez1 in the hippocampus of HDAC11 knockout mice
Histone Deacetylase 11 (HDAC11) is highly expressed in the central nervous system where it has been reported to have roles in neural differentiation. In contrast with previous studies showing nuclear and cytoplasmic localisation, we observed synaptic enrichment of HDAC11. Knockout mouse models for HDACs 1–9 have been important for guiding the development of isoform specific HDAC inhibitors as effective therapeutics. Given the close relationship between HDAC11 and neural cells in vitro, we examined neural tissue in a previously uncharacterised Hdac11 knockout mouse (Hdac11KO/KO). Loss of HDAC11 had no obvious impact on brain morphology and neural stem/precursor cells isolated from Hdac11KO/KO mice had comparable proliferation and differentiation characteristics. However, in differentiating neural cells we observed decreased expression of schizophrenia-associated gene Fez1 (fasciculation and elongation protein zeta 1), a gene previously reported to be regulated by HDAC11 activity. FEZ1 has been associated with the dendritic growth of neurons and risk of schizophrenia via its interaction with DISC1 (disrupted in schizophrenia 1). Examination of cortical, cerebellar and hippocampal tissue reveal decreased Fez1 expression specifically in the hippocampus of adult mice. The results of this study demonstrate that loss of HDAC11 has age dependent and brain-region specific consequences.
- 13 September 2016
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 87 (Suppl 1) , A11.3-A12
B8 Ablation of p62 modulates levels of soluble and aggregated mutant huntingtin and delays end-stage disease in R6/2 mice
Background N-terminal fragments of the mutant huntingtin (HTT) protein aggregate into oligomeric and fibrillary structures that can be detected as polyubiquitylated inclusion bodies in tissue sections from HD patients and mouse models of HD. Misfolded and aggregated proteins are degraded through two main intracellular protein clearance systems, the ubiquitin–proteasome system (UPS) and the autophagy–lysosome pathway. p62 is an adapter protein that regulates the proteolysis of ubiquitylated proteins via selective autophagy. In both the R6/2 and HdhQ150 knock-in mice, p62 relocates to the nucleus with disease progression where it forms high molecular weight structures and co-localises with HTT inclusions. Aims To investigate the effect of the constitutive ablation of the p62 gene on HD-related phenotypes in the R6/2 mouse model of HD. Methods R6/2 mice that were heterozygous for p62 knock-out (p62Het) to p62Het females to generate WT, p62Het, p62 homozygous knock-out (p62Hom); R6/2, R6/2::p62Het and R6/2::p62Hom progeny. The effect of p62 ablation was assessed by multiple biochemical, immunohistochemical and behavioural approaches. Results We have been able to demonstrate that the levels of soluble and aggregated HTT are decreased in multiple brain regions of R6/2::p62Hom mice, as compared to their R6/2 littermates and that this effect becomes more pronounced with disease progression. Ablation of p62 in R6/2 mice did not modify the failure of R6/2 mice to gain body weight, or impairments in rotarod performance, grip strength or activity but did delay end-stage disease as previously reported (Kurosawa et al., 2014). Similarly, ablation of p62 did not improve dysregulated transcriptional profiles. Conclusion Unravelling the mechanism by which the manipulation of p62 modulates soluble and aggregated HTT levels will lead to a greater understanding of the aggregation and clearance of mutant HTT. Funding CHDI Foundation
- 13 September 2016
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 87 (Suppl 1) , A11.3-A12
B8 Ablation of p62 modulates levels of soluble and aggregated mutant huntingtin and delays end-stage disease in R6/2 mice
Background N-terminal fragments of the mutant huntingtin (HTT) protein aggregate into oligomeric and fibrillary structures that can be detected as polyubiquitylated inclusion bodies in tissue sections from HD patients and mouse models of HD. Misfolded and aggregated proteins are degraded through two main intracellular protein clearance systems, the ubiquitin–proteasome system (UPS) and the autophagy–lysosome pathway. p62 is an adapter protein that regulates the proteolysis of ubiquitylated proteins via selective autophagy. In both the R6/2 and HdhQ150 knock-in mice, p62 relocates to the nucleus with disease progression where it forms high molecular weight structures and co-localises with HTT inclusions. Aims To investigate the effect of the constitutive ablation of the p62 gene on HD-related phenotypes in the R6/2 mouse model of HD. Methods R6/2 mice that were heterozygous for p62 knock-out (p62Het) to p62Het females to generate WT, p62Het, p62 homozygous knock-out (p62Hom); R6/2, R6/2::p62Het and R6/2::p62Hom progeny. The effect of p62 ablation was assessed by multiple biochemical, immunohistochemical and behavioural approaches. Results We have been able to demonstrate that the levels of soluble and aggregated HTT are decreased in multiple brain regions of R6/2::p62Hom mice, as compared to their R6/2 littermates and that this effect becomes more pronounced with disease progression. Ablation of p62 in R6/2 mice did not modify the failure of R6/2 mice to gain body weight, or impairments in rotarod performance, grip strength or activity but did delay end-stage disease as previously reported (Kurosawa et al., 2014). Similarly, ablation of p62 did not improve dysregulated transcriptional profiles. Conclusion Unravelling the mechanism by which the manipulation of p62 modulates soluble and aggregated HTT levels will lead to a greater understanding of the aggregation and clearance of mutant HTT. Funding CHDI Foundation
- Open Access
- 26 February 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (2) , e0150682
Correction: SIRT1 Activity Is Linked to Its Brain Region-Specific Phosphorylation and Is Impaired in Huntington's Disease Mice
[This corrects the article DOI: 10.1371/journal.pone.0145425.].
- 26 February 2016
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (2) , e0150682
Open AccessCorrection: SIRT1 Activity Is Linked to Its Brain Region-Specific Phosphorylation and Is Impaired in Huntington's Disease Mice
[This corrects the article DOI: 10.1371/journal.pone.0145425.].
- 22 January 2013
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 110 (6) , 2366-2370
Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease
Huntington disease (HD) is a devastating, late-onset, inherited neurodegenerative disorder that manifests with personality changes, movement disorders, and cognitive decline. It is caused by a CAG repeat expansion in exon 1 of the HTT gene that translates to a polyglutamine tract in the huntingtin protein (HTT). The formation of HTT fragments has been implicated as an essential step in the molecular pathogenesis of HD and several proteases that cleave HTT have been identified. However, the importance of smaller N-terminal fragments has been highlighted by their presence in HD postmortem brains and by the fact that nuclear inclusions are only detected by antibodies to the N terminus of HTT. Despite an intense research effort, the precise length of these fragments and the mechanism by which they are generated remains unknown. Here we show that CAG repeat length–dependent aberrant splicing of exon 1 HTT results in a short polyadenylated mRNA that is translated into an exon 1 HTT protein. Given that mutant exon 1 HTT proteins have consistently been shown to be highly pathogenic in HD mouse models, the aberrant splicing of HTT mRNA provides a mechanistic basis for the molecular pathogenesis of HD. RNA-targeted therapeutic strategies designed to lower the levels of HTT are under development. Many of these approaches would not prevent the production of exon 1 HTT and should be reviewed in light of our findings.
- 22 January 2013
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 110 (6) , 2366-2370
Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease
Huntington disease (HD) is a devastating, late-onset, inherited neurodegenerative disorder that manifests with personality changes, movement disorders, and cognitive decline. It is caused by a CAG repeat expansion in exon 1 of the HTT gene that translates to a polyglutamine tract in the huntingtin protein (HTT). The formation of HTT fragments has been implicated as an essential step in the molecular pathogenesis of HD and several proteases that cleave HTT have been identified. However, the importance of smaller N-terminal fragments has been highlighted by their presence in HD postmortem brains and by the fact that nuclear inclusions are only detected by antibodies to the N terminus of HTT. Despite an intense research effort, the precise length of these fragments and the mechanism by which they are generated remains unknown. Here we show that CAG repeat length–dependent aberrant splicing of exon 1 HTT results in a short polyadenylated mRNA that is translated into an exon 1 HTT protein. Given that mutant exon 1 HTT proteins have consistently been shown to be highly pathogenic in HD mouse models, the aberrant splicing of HTT mRNA provides a mechanistic basis for the molecular pathogenesis of HD. RNA-targeted therapeutic strategies designed to lower the levels of HTT are under development. Many of these approaches would not prevent the production of exon 1 HTT and should be reviewed in light of our findings.